U.S. flag

An official website of the United States government

NM_002524.5(NRAS):c.112-1_113dup AND RASopathy

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Nov 29, 2012
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000158984.8

Allele description [Variation Report for NM_002524.5(NRAS):c.112-1_113dup]

NM_002524.5(NRAS):c.112-1_113dup

Gene:
NRAS:NRAS proto-oncogene, GTPase [Gene - OMIM - HGNC]
Variant type:
Duplication
Cytogenetic location:
1p13.2
Genomic location:
Preferred name:
NM_002524.5(NRAS):c.112-1_113dup
HGVS:
  • NC_000001.11:g.114713978_114713980dup
  • NG_007572.1:g.7916_7918dup
  • NM_002524.5:c.112-1_113dupMANE SELECT
  • LRG_92t1:c.112-1_113dup
  • LRG_92:g.7916_7918dup
  • NC_000001.10:g.115256599_115256601dup
  • NM_002524.3:c.112-1_113dup
  • NM_002524.3:c.112-1_113dupGGA
  • p.E37dup
Links:
dbSNP: rs730880967
NCBI 1000 Genomes Browser:
rs730880967
Molecular consequence:
  • NM_002524.5:c.112-1_113dup - splice acceptor variant - [Sequence Ontology: SO:0001574]

Condition(s)

Name:
RASopathy
Synonyms:
rasopathies; Noonan spectrum disorder
Identifiers:
MONDO: MONDO:0021060; MedGen: C5555857

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000208923GeneDx
criteria provided, single submitter

(GeneDx Variant Classification (06012015))
Pathogenic
(Nov 29, 2012)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From GeneDx, SCV000208923.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

This mutation is denoted c.112-1_113dupGGA at the cDNA level or at the protein level as p.Glu37dup (E37dup) in exon 3 of the NRAS gene (NM_002524.3). This is a duplication of three nucleotides at the boundary of intron 2 and exon 3 in the NRAS gene. Using lowercase letters to denote intronic sequence and uppercase letters to denote exonic sequence, the normal sequence with the bases that are inserted in braces is: agGA{insGGA}TTCT. The c.112-1_113dupGGA mutation likely associated with a Noonan spectrum disorder was identified in the NRAS gene. It has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. However, a similar type of mutation (p.E37dup) has been observed as a de novo mutation in two unrelated patients with Costello syndrome in the HRAS gene, a closely related RAS signal transduction protein in the RAS/MAPK pathway (Gremer et al., 2010). In vitro studies of p.E37dup in HRAS have been shown to alter HRAS function and the activity of downstream pathways (Gremer et al., 2010). The c.112-1_113dupGGA in the NRAS gene leads to an in-frame duplication of a Glutamic Acid at position 37, the first codon in exon 3. This duplication is expected to alter the structure and function of NRAS. The variant is found in NOONAN panel(s).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 3, 2024